Tirofiban
- Generic Name
- Tirofiban
- Brand Names
- Aggrastat
- Drug Type
- Small Molecule
- Chemical Formula
- C22H36N2O5S
- CAS Number
- 144494-65-5
- Unique Ingredient Identifier
- GGX234SI5H
- Background
Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.
- Indication
For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy.
- Associated Conditions
- Cardiovascular Events
Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden
- Conditions
- ST-segment Elevation Myocardial Infarction (STEMI)
- Interventions
- Drug: rhTNK-tPA, 4-8 mg
- First Posted Date
- 2025-01-10
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Henan Institute of Cardiovascular Epidemiology
- Target Recruit Count
- 300
- Registration Number
- NCT06769256
- Locations
- 🇨🇳
Fuwai Central China Cardiovascular Hospital, Zhengzhou, Henan, China
Tirofiban for the Prevention of Early Neurological Deterioration After Intravenous Thrombolysis in Acute Ischemic Stroke
- Conditions
- Acute StrokeIschemic Stroke, AcuteCerebral Infarction
- Interventions
- Drug: Standard medical treatment (SMT)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Capital Medical University
- Target Recruit Count
- 302
- Registration Number
- NCT06587347
- Locations
- 🇨🇳
Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China
Tirofiban for Successful Endovascular Stroke Thrombectomy
- Conditions
- Stroke, Acute Ischemic
- Interventions
- Drug: Intraarterial and intravenous placebo
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Zhongming Qiu
- Target Recruit Count
- 712
- Registration Number
- NCT06373042
Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4）
- Conditions
- Symptomatic Intracranial Artery StenosisIschemic Stroke, AcuteTIA
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 4674
- Registration Number
- NCT06319846
- Locations
- 🇨🇳
The 2nd Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
🇨🇳People's Hospital of Qihe County, Dezhou, Shandong, China
🇨🇳Liaocheng People's Hospital（Liaocheng Brain Hospital）, Liaocheng, Shandong, China
Tirofiban After Successful MT Recanalization in AIS
- Conditions
- Acute Ischemic StrokeVessel Occlusion
- Interventions
- Drug: Saline placebo
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Xiang Luo
- Target Recruit Count
- 1360
- Registration Number
- NCT06265051
- Locations
- 🇨🇳
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair
- Conditions
- Unruptured Intracranial AneurysmStent-assisted CoilingFlow DiverterThromboembolic Events
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 190
- Registration Number
- NCT06238115
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Beijing, China
Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke
- Conditions
- Acute Ischemic Stroke
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 1084
- Registration Number
- NCT06045156
- Locations
- 🇨🇳
The first hospital of Jilin University, Chang chun, Jilin, China
Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)
- Conditions
- Branch Atheromatous Disease
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 516
- Registration Number
- NCT06037889
- Locations
- 🇨🇳
Chengde Central Hospital, Chengde, Hebei, China
🇨🇳Beijing Shijitan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳The First Hospital of Tsinghua University, Beijing, Beijing, China
Reduction of Microembolism After the Intervention Surgery of Intracranial Aneurysms by Administration of Tirofiban
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Lu Hua
- Target Recruit Count
- 70
- Registration Number
- NCT05841147
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, China
Intravenous Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Stroke
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Xinqiao Hospital of Chongqing
- Target Recruit Count
- 800
- Registration Number
- NCT05728333
- Locations
- 🇨🇳
Hangzhou First People's Hospital, Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.